Torrent Pharma earnings for the quarter ended September 30, 2026, showed net profit falling 10% year on year to ₹534 crore, despite revenue rising 50.8% to ₹4,979 crore. The October 23 results reflected the addition of JB Chemicals & Pharmaceuticals, alongside growth in Torrent’s base business, but integration temporarily disrupted revenue.
Key Takeaways
- Base-business revenue grew 18%, compared with total revenue growth of 50.8% after JB’s inclusion.
- Operating EBITDA before exceptional items rose 53.8%, while net profit declined.
- Torrent described the revenue impact from JB integration as temporary.
Table of Contents
- Torrent Pharma earnings show stronger operations, lower net profit
- JB integration changes the revenue comparison
- Base-business growth varies across markets
- Conclusion
Torrent Pharma earnings show stronger operations, lower net profit
Revenue from operations increased from ₹3,302 crore in the year-earlier quarter. Operating EBITDA before exceptional items reached ₹1,666 crore, with its margin improving to 33.5% from 32.8%. Gross margin stood at 75.4%.
The figures show that stronger sales and operating profitability did not translate into higher bottom-line earnings. The available results summary does not provide a full reconciliation explaining the net-profit decline.
Torrent’s Q2 FY27 earnings materials include consolidated and standalone results, a press release and a conference-call recording for the quarter and half year ended September 30, 2026.
| Item | Details |
|---|---|
| Base India business | Q2 FY27 revenue of ₹2,181 crore, up 20% year on year. |
| Base Brazil business | Q2 FY27 revenue of ₹440 crore, up 38% year on year. |
| Base US business | Q2 FY27 revenue of ₹417 crore, up 24% year on year. |
| Base Germany business | Q2 FY27 revenue of ₹283 crore, down 7% year on year. |
JB integration changes the revenue comparison
Torrent’s base business generated ₹3,893 crore in quarterly revenue, up 18%, while the JB business contributed ₹1,086 crore. Separating those figures helps distinguish growth in the existing business from the expansion associated with the merger.
Torrent said the merger became effective on July 8, 2026. Integration of the India business, optimisation of the global business network, and alignment of manufacturing and quality-management systems had a temporary impact on second-quarter revenue, the company said.
JB’s India prescription business, excluding trade generics and contrast media, grew 7% to ₹597 crore. Its international business, including the US, emerging markets and contract development and manufacturing operations, declined 7% to ₹406 crore.
Base-business growth varies across markets
Torrent’s base India business grew faster than the domestic pharmaceutical market: revenue increased 20%, compared with market growth of 12% in the PharmaTrac dataset. Brazil and the US also expanded, while Germany declined because of supply disruptions at a third-party supplier and the loss of certain high-volume tenders.
For the first half of FY27, revenue rose 52.8% to ₹9,900 crore and operating EBITDA increased 57.4% to ₹3,330 crore. The operating EBITDA margin reached 33.6%, but net profit fell 3.4% to ₹1,100 crore.
Quarterly research and development spending increased 35% to ₹211 crore, equivalent to 4.2% of revenue. Torrent shares closed 2.78% lower at ₹4,482 on the BSE on October 23.
Conclusion
The next results will provide a test of whether the integration-related revenue disruption eases. For now, Torrent’s stronger base-business sales and operating margin stand alongside lower net profit, rather than a broad improvement across every earnings measure.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
